PD vs SMMT: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

SMMT is the larger of the two ($8.01B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta -1.52). PD is the smaller challenger ($1.19B), expected to make money next year (10.29x forward earnings): more room to run, but more to prove. If you believe in growth, SMMT fits: analysts expect its revenue to rise 2353% next year, against 2% for PD. If you believe in profit, PD fits: it is expected to make money next year (10.29x forward earnings), while SMMT is still expected to post a loss.

PD vs SMMT: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricPDSMMTWhat it tells you
Market cap$1.19B$8.01BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E10.29-9.51Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.95-1.52Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range76% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.0714.19How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how PD and SMMT affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PD and SMMT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PD and SMMT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does PagerDuty (PD) do?

PagerDuty sells the software that wakes engineers up. When a payment system, a checkout flow or an internal API breaks, PagerDuty ingests the alert from monitoring tools, decides who is on call, escalates until a human acknowledges it, and coordinates the response through to a postmortem. Around that core it has added runbook automation (from its 2020 Rundeck purchase), an AIOps layer that groups noisy alerts into single incidents, customer service operations tooling, and more recently a set of agentic features: in November 2026 it unveiled Paige, an SRE agent, alongside a rebranded PD Reliability Platform and a PD Labs unit for open AI work in reliability engineering. Roughly 15,500 paying customers use it, of which about 884 spend more than ~$100,000 a year, and annual recurring revenue sits near ~$501 million.

Full PD guide

What does Summit Therapeutics (SMMT) do?

Summit Therapeutics is a clinical-stage biopharmaceutical company focused almost entirely on ivonescimab, a first-in-class tetravalent bispecific antibody that targets both PD-1 and VEGF simultaneously. Summit in-licensed ivonescimab from China's Akeso in January 2023 and holds rights to develop and commercialize it across North America, South America, Europe, the Middle East, Africa, and Japan, while Akeso keeps China and certain other regions. The lead opportunity is non-small cell lung cancer (NSCLC), where Phase III data in China have shown ivonescimab extending progression-free survival versus Merck's Keytruda (pembrolizumab), plus additional programs in colorectal and other cancers. The company generates no meaningful product revenue yet and funds operations from its cash balance while running large global trials.

Full SMMT guide

PD vs SMMT: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • PD drivers: Margin and cash generation from a flat revenue base; A new chief executive and a go-to-market reset.
  • SMMT drivers: Ivonescimab FDA review and first approval; Head-to-head data versus Keytruda.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The core problem is demand, not costs: dollar-based net retention of ~98% means the existing customer base is shrinking slightly net of expansion, so new logos are doing the work of holding revenue flat. For SMMT, summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab, and the November 2026 FDA rejection shows that risk is real: the agency found the benefit modest relative to safety risks and asked for a new trial, which delays any US launch by years if the next data are positive and could end the US program if they are not.

PD or SMMT: which should you pick?

If the story you believe is PD's (Margin and cash generation from a flat revenue base), PD is the more direct way to own it; if it is SMMT's (Ivonescimab FDA review and first approval), SMMT is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PD and SMMT guides.

PD vs SMMT: the full fundamentals

PD. Two numbers explain most of the debate around PD. Revenue growth under 1% with retention below 100% is what kept the multiple under ~2x sales through the summer, while a ~23.7% non-GAAP operating margin and real free cash flow are what kept a floor under it. At about $15.08 (November 20, 2026) the stock trades near 2.4x sales and about 10x analysts' forward EPS of ~$1.47, somewhat below the mid-October peak multiple. Consensus for fiscal 2027 is ~$1.36 of EPS on ~$494 million of revenue, so profitability is expected to do the improving, and the December 3 report will show whether that holds.

SMMT. As a clinical-stage biotech with no meaningful product sales, Summit cannot be valued on earnings or a P/E ratio; its roughly $8.0 billion market value (November 20, 2026) reflects expectations for ivonescimab outside the now-delayed US filing. AstraZeneca's implied $18.36 a share is about 83% above the November 20 close, while Bernstein's new $8.30 target sits below it, and the 13-analyst mean target near $29 largely predates the rejection. Figures are approximate; the November 30 corporate update is the next scheduled event.

Headline figures (approximate, November 2026): PD shows revenue (ttm) ~$495 million, q2 fy2027 revenue (quarter ended july 31, 2026) ~$124.4 million, up ~0.8% year over year, annual recurring revenue / net retention ~$501 million ARR, dollar-based net retention ~98%, profitability ~85% gross margin; GAAP operating margin ~6.8% (TTM); non-GAAP operating margin ~23.7% last quarter; non-GAAP diluted EPS ~$0.32 (est. ~$0.31); SMMT shows product revenue (ttm) ~$0 (pre-commercial), net loss (ttm) ~-$833 million; Q3 2026 net loss ~-$155 million ($0.19 per share vs ~$0.21 est.), cash (september 30, 2026) ~$630 million, before AstraZeneca's $2 billion (closed Oct 5, 2026), astrazeneca investment $2 billion at an implied $18.36 per share (~109 million common equivalents).

The bottom line: PD vs SMMT

PD and SMMT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined PD and SMMT exposure against your real portfolio. It is not an investment adviser.

Wondering how PD or SMMT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about PagerDuty

Ask Walnut's AI anything about PD and see how it fits what you own.

FAQ

What is the difference between PD and SMMT?

+

PagerDuty sells the software that wakes engineers up. Summit Therapeutics is a clinical-stage biopharmaceutical company focused almost entirely on ivonescimab, a first-in-class tetravalent bispecific antibody that targets both PD-1 and VEGF simultaneously. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is PD or SMMT the better stock?

+

Neither is universally better. SMMT is the larger incumbent; PD is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, PD or SMMT?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both PD and SMMT?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of PD vs SMMT?

+

PD: The core problem is demand, not costs: dollar-based net retention of ~98% means the existing customer base is shrinking slightly net of expansion, so new logos are doing the work of holding revenue flat. Seat-based pricing ties PagerDuty to engineering headcount at technology companies, a line item that has been cut repeatedly since 2023 and that AI coding tools may keep suppressing. Competitively, the pressure comes from bundling rather than from a better product: Datadog now ships its own on-call module, Atlassian folds Opsgenie capability into Jira Service Management, and both can price incident management as an add-on to a platform a customer already buys. Glancy Prongay & Murray announced a securities-fraud investigation in December 2025 after the November 25, 2025 results, when the shares fell about 23% on disclosure of weakening demand and retention, and while no class action complaint has been filed to date, the underlying facts it points at are the same growth facts above. Convertible debt sits against the cash balance (Yahoo Finance shows about ~$413 million of debt versus ~$470 million of cash and investments), so the gross cash figure overstates the net position, and any reader should check the current note terms in the latest 10-Q rather than assume them away. Valuation risk has also risen: even after a one-month pullback of about 14% the stock trades above the average analyst target of about $13.43, and the trailing P/E of about 7.5x flatters it because trailing net income of ~$186 million includes a single quarter of about $160 million in late 2025, far above the ~$5 million to ~$11 million of recent quarters. SMMT: Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab, and the November 2026 FDA rejection shows that risk is real: the agency found the benefit modest relative to safety risks and asked for a new trial, which delays any US launch by years if the next data are positive and could end the US program if they are not. Further failed trials, negative regulatory decisions in other regions, or unexpected safety findings could sharply reduce the company's value again. The competitive field is intensifying, with Pfizer/3SBio and Bristol Myers Squibb/BioNTech (pumitamig) also developing PD-1/PD-L1 by VEGF bispecifics, and Merck's Keytruda is the entrenched standard of care; a longer US timeline gives rivals room to catch up. The company depends on its license from Akeso and on manufacturing and clinical execution across many regions. AstraZeneca's $2 billion investment eases funding pressure, but it was itself dilutive, and with net losses running about $140-165 million a quarter and no product sales, further raises remain possible over a longer development path. The stock is highly volatile and prone to large single-day moves around catalysts; it fell about 35% in the month to November 20, 2026.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell PD or SMMT; figures are approximate and dated (as of November 2026). Verify current data before investing.